Progress is on the horizon for the GBM field as innovative therapies and a deeper understanding of glioblastoma biology begin to emerge. Servier’s recent approval of vorasidenib for Grade 2 IDH-mutant glioma has sparked renewed hope in a space that has long struggled with limited treatment options. This milestone brings inspiration to the glioblastoma community, where the urgent need for effective treatments remains.

As we look toward 2025, a year that could mark a turning point in glioblastoma treatment, it is more important than ever to unite the community and deepen our understanding of these critical developments. Securing new treatment approvals for patients who desperately need them is a mission that cannot wait.

The 6th Glioblastoma Drug Development Summit was the only industry-led event that brought together 90+ experts from pharma, biotech, neuro-oncology, clinical practice, investment, and academia. With a shared goal of improving the lives of patients, this Summit fostered collaboration to advance the development of effective therapies for GBM and other CNS tumors.

Attendees joined us as we uncovered the latest clinical and preclinical advancements, addressed the challenges of securing funding, and explored big pharma's priorities for partnerships and combination therapies. They were a part of this pivotal gathering that helped shape what could have been a transformational year for glioblastoma in 2025.